Exhibit 99.1

STERIS plc Announces Fiscal 2016 Third Quarter Financial Results

• Revenue growth of 31%, with 7% constant currency organic growth

• Synergy Health integration on track

• Record revenue and earnings and fiscal 2016 outlook confirmed

LEICESTER, U.K. – February 9, 2016 – STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2016 third quarter ended December 31, 2015. Fiscal 2016 third quarter revenue increased 31% to $618.7 million compared with $473.2 million for STERIS Corporation (“Old STERIS”) in the third quarter of fiscal 2015, with 7% constant currency organic growth. As reported, operating income was $46.7 million, compared with operating income of $61.3 million for Old STERIS for the third quarter of fiscal 2015. As reported, net income was $20.0 million, or $0.26 per diluted share, compared with net income of $38.1 million, or $0.63 per diluted share for Old STERIS in the third quarter of fiscal 2015. All succeeding references to results from prior year periods are for Old STERIS.

Adjusted Results

Adjusted net income for the third quarter of fiscal 2016 was $76.2 million, or $0.98 per diluted share, compared with adjusted net income for the third quarter of the previous year of $47.7 million, or $0.79 per diluted share. The improvement in net income reflects the Combination with Synergy Health, improved operating performance and a lower effective tax rate.

“Our performance in the third quarter reflects solid organic revenue growth and contributions from recent acquisitions,” said Walt Rosebrough, President and Chief Executive Officer of STERIS. “The integration efforts for Synergy Health are progressing well, and we believe we are positioned to meet the record revenue and adjusted earnings full-year guidance we gave in December.”

Segment Results

Beginning this quarter, STERIS is reporting four business segments:

• Healthcare Products—Infection prevention and procedural solutions for healthcare providers worldwide, including capital equipment and related maintenance and installation services, as well as consumables.

• Healthcare Specialty Services—A range of specialty services for healthcare providers including hospital sterilization services, instrument and scope repair, and linen management.

• Applied Sterilization Technologies—Contract sterilization and laboratory services for medical device and pharmaceutical Customers and others.

• Life Sciences—Capital equipment and consumable products, and equipment maintenance and specialty services, for pharmaceutical manufacturers and research.

Healthcare Products revenue grew 10% in the quarter to $317.1 million compared with $287.5 million in the third quarter of fiscal 2015 reflecting organic volume growth and acquisitions. Contributing to the quarter, consumable revenue grew 15%, capital equipment revenue increased 12% and service revenue grew 3%. Healthcare Products operating income was $52.1 million compared with $42.7 million in last year’s third quarter. The increase in profitability was primarily due to increased volume and favorable foreign currency exchange rates.

Healthcare Specialty Services revenue in the quarter was $128.3 million compared with $65.7 million in the third quarter of fiscal 2015, reflecting the addition of Synergy Health and organic volume growth. Healthcare Specialty Services operating income was $7.4 million compared with $5.2 million in last year’s third quarter. The increase in profitability was primarily due to the increased volume.

2

Fiscal 2016 third quarter revenue for Applied Sterilization Technologies was $90.2 million compared with $51.0 million in the same period last year. Revenue benefited from the addition of Synergy Health and increased volume from the segment’s core medical device Customers. Segment operating income increased to $26.8 million in the third quarter of fiscal 2016 compared with operating income of $14.0 million last year, due primarily to the increase in volume and the addition of Synergy Health.

Life Sciences third quarter revenue increased 22% to $82.7 million compared with $68.0 million in the third quarter of fiscal 2015. Consumable revenue grew 45%, reflecting organic growth and the acquisition of GEPCO, capital equipment revenue increased 8% and service revenue grew 13%. Segment operating income was $24.1 million compared with $16.5 million in the prior year quarter. The increase in profitability was primarily due to the increased volume, including GEPCO, and favorable foreign currency exchange rates.

Cash Flow

Net cash provided by operations for the first nine months of fiscal 2016 was $104.6 million, compared with $165.2 million in fiscal 2015. Free cash flow (see Non-GAAP Financial Measures) for the first nine months of fiscal 2016 was $22.9 million compared with $109.3 million in the prior year. The decline in free cash flow is primarily due to expenses related to the combination with Synergy Health and other acquisitions. In addition, free cash flow was reduced by an increased payout level for the Company’s prior year annual compensation program and a pension contribution made for the settlement of a legacy pension obligation. The total of these items, which reduced free cash flow year-over-year, is approximately $85 million.

Outlook

The Company is reiterating its outlook provided on December 22, 2015, which includes revenue growth of 21%-22% for the full fiscal 2016 year and adjusted earnings per diluted share in the range of $3.48 to $3.55. The Company currently anticipates free cash flow of approximately $100 million in fiscal 2016, reflecting approximately $100 million in acquisition and integration related costs.

3

Dividend Announcement

The Company also announced today that STERIS’s Board of Directors has authorized a quarterly dividend of $0.25 per common share. The dividend is payable March 29, 2016 to shareholders of record at the close of business on March 1, 2016.

Conference Call

In conjunction with this release, STERIS management will host a conference call today at 10:00 a.m. Eastern time. The conference call can be heard live over the Internet at www.steris-ir.com or via phone by dialing 1-800-369-8428 in the United States and Canada, and 1-773-799-3378 internationally, then referencing the password “STERIS”.

For those unable to listen to the conference call live, a replay will be available beginning at 12:00 p.m. Eastern time today either over the Internet at www.steris-ir.com or via phone by calling 1-866-408-8448 in the United States and Canada, and 1-203-369-0632 internationally.

About STERIS

STERIS’s mission is to help our Customers create a healthier and safer world by providing innovative healthcare and life science product and service solutions around the globe. For more information, visit www.steris.com.

Investor Contact:

Julie Winter, Director, Investor Relations

Julie_Winter@steris.com

+1 440 392 7245

Media Contact:

Stephen Norton, Senior Director, Corporate Communications

Stephen_Norton@steris.com

+1 440 392 7482

4

Non-GAAP Financial Measures

Adjusted net income and free cash flow are non-GAAP measures that may be used from time to time and should not be considered replacements for GAAP results. Non-GAAP financial measures are presented in this release with the intent of providing greater transparency to supplemental financial information used by management and the Board of Directors in their financial analysis and operational decision making. These amounts are disclosed so that the reader has the same financial data that management uses with the belief that it will assist investors and other readers in making comparisons to our historical operating results and analyzing the underlying performance of our operations for the periods presented. The Company believes that the presentation of these non-GAAP financial measures, when considered along with our GAAP financial measures, provides a more complete understanding of the factors and trends affecting our business than could be obtained absent this disclosure.

Adjusted net income excludes the amortization of intangible assets acquired in business combinations, acquisition-related transaction costs, integration costs related to acquisitions, and certain other unusual or non-recurring items. STERIS believes this measure is useful because it excludes items that may not be indicative of or are unrelated to our core operating results and provides a baseline for analyzing trends in our underlying businesses.

The Company defines free cash flow as cash flows from operating activities less purchases of property, plant, equipment and intangibles, net capital expenditures, plus proceeds from the sale or property, plant, equipment, and intangibles. STERIS believes that free cash flow is a useful measure of the Company’s ability to fund future principal debt repayments and growth outside of core operations, pay cash dividends, and repurchase ordinary shares.

Forward-Looking Statements

This release and the conference call may contain statements concerning certain trends, expectations, forecasts, estimates, or other forward-looking information affecting or relating to STERIS or its industry, products or activities that are intended to qualify for the protections afforded “forward-looking statements” under the Private Securities Litigation Reform Act of 1995 and other laws and regulations. Forward-looking statements speak only as to the date specified in this release and may be identified by the use of forward- looking terms such as “may,” “will,” “expects,” “believes,” “anticipates,” “plans,” “estimates,” “projects,” “targets,” “forecasts,” “outlook,” “impact,” “potential,” “confidence,” “improve,” “optimistic,” “deliver,” “comfortable,” “trend”, and “seeks,” or the negative of such terms or other variations on such terms or comparable terminology. Many important factors could cause actual results to differ materially from those in the forward-looking statements including, without limitation, disruption of production or supplies, changes in market conditions, political events, pending or future claims or litigation, competitive factors, technology advances, actions of regulatory agencies, and changes in laws, government regulations, labeling or product approvals or the application or

5

interpretation thereof. Other risk factors are described herein and in STERIS’s, STERIS Corporation’s and Synergy’s other securities filings, including Item 1A of STERIS Corporation’s Annual Report on Form 10-K for the year ended March 31, 2015 and in Synergy’s annual report and accounts for the year ended 29 March 2015 (section headed “principal risks and uncertainties”). Many of these important factors are outside of STERIS’s control. No assurances can be provided as to any result or the timing of any outcome regarding matters described in the press release or otherwise with respect to any regulatory action, administrative proceedings, government investigations, litigation, warning letters, cost reductions, business strategies, earnings or revenue trends or future financial results. References to products are summaries only and should not be considered the specific terms of the product clearance or literature. Unless legally required, STERIS does not undertake to update or revise any forward-looking statements even if events make clear that any projected results, express or implied, will not be realized. Other potential risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, (a) STERIS’s ability to meet expectations regarding the accounting and tax treatments of the Combination, (b) the possibility that the parties may be unable to achieve expected synergies and operating efficiencies in connection with the Combination within the expected time-frames or at all and to successfully integrate Synergy’s operations with those of STERIS Corporation, (c) the integration of Synergy’s operations with those of STERIS Corporation being more difficult, time-consuming or costly than expected, (d) operating costs, customer loss and business disruption (including, without limitation, difficulties in maintaining relationships with employees, customers, clients or suppliers) being greater than expected following the transaction, (e) the retention of certain key employees of Synergy being difficult, (f) changes in tax laws or interpretations that could increase our consolidated tax liabilities, including, changes in tax laws that would result in STERIS being treated as a domestic corporation for United States federal tax purposes, (g) the potential for increased pressure on pricing or costs that leads to erosion of profit margins, (h) the possibility that market demand will not develop for new technologies, products or applications or services, or business initiatives will take longer, cost more or produce lower benefits than anticipated, (i) the possibility that application of or compliance with laws, court rulings, certifications, regulations, regulatory actions, including without limitation those relating to FDA warning notices or letters, government investigations, the outcome of any pending FDA requests, inspections or submissions, or other requirements or standards may delay, limit or prevent new product introductions, affect the production and marketing of existing products or services or otherwise affect STERIS’s performance, results, prospects or value, (j) the potential of international unrest, economic downturn or effects of currencies, tax assessments, adjustments or anticipated rates, raw material costs or availability, benefit or retirement plan costs, or other regulatory compliance costs, (k) the possibility of reduced demand, or reductions in the rate of growth in demand, for STERIS’s products and services, (l) the possibility that anticipated growth, cost savings, new product acceptance, performance or approvals, or other results may not be achieved, or that transition, labor, competition, timing, execution, regulatory, governmental, or other issues or risks associated with STERIS’s businesses, industry or initiatives including, without limitation, those matters described in STERIS Corporation’s Form 10-K for the year ended March 31, 2015 and Synergy’s annual report and accounts for the year ended 29 March 2015 and other securities filings, may adversely impact STERIS’s performance, results, prospects or value, (m) the possibility that anticipated financial results or benefits of recent acquisitions, including the Combination, or of STERIS’s restructuring efforts will not be realized or will be other than anticipated and (n) the effects of the contractions in credit availability, as well as the ability of STERIS’s Customers and suppliers to adequately access the credit markets when needed.

6

STERIS plc

Consolidated Condensed Statements of Operations

(In thousands, except per share data)

	Three Months Ended December 31,						Nine Months Ended December 31,
	2015			2014			2015			2014
	(Unaudited)			(Unaudited)			(Unaudited)			(Unaudited)
Revenues	$	618,688		$	473,244		$	1,548,487		$	1,348,616
Cost of revenues		380,506			276,055			916,576			787,792
Cost of revenues—Restructuring		1			33			319			(417	)
Cost of revenues, net		380,507			276,088			916,895			787,375
Gross profit		238,181			197,156			631,592			561,241
Operating expenses:
Selling, general, and administrative		177,319			122,370			476,613			362,350
Research and development		14,334			14,549			42,354			39,964
Restructuring expense		(194	)		(1,109	)		(976	)		(10	)
Total operating expenses		191,459			135,810			517,991			402,304
Income from operations		46,722			61,346			113,601			158,937
Non-operating expense, net		17,300			4,405			30,196			13,779
Income tax expense		8,268			18,817			29,689			51,493
Net income		21,154			38,124			53,716			93,665
Net income attributable to non controlling interest		1,109			—			693			—
Net income attributable to shareholders	$	20,045		$	38,124		$	53,023		$	93,665
Earnings per common share (EPS) data:
Basic	$	0.26		$	0.64		$	0.81		$	1.58
Diluted	$	0.26		$	0.63		$	0.80		$	1.56
Cash dividends declared per share outstanding	$	0.25		$	0.23		$	0.73		$	0.67
Weighted average number of shares outstanding used in EPS computation:
Basic number of shares outstanding		77,221			59,475			65,629			59,340
Diluted number of shares outstanding		77,712			60,146			66,123			59,993

STERIS plc

Consolidated Condensed Balance Sheets

(In thousands)

	December 31,		March 31,
	2015		2015
	(Unaudited)
Assets
Current assets:
Cash and cash equivalents	$	231,360	$	167,689
Accounts receivable, net		440,858		325,289
Inventories, net		208,306		160,818
Other current assets		85,184		66,636
Total Current Assets		965,708		720,432
Property, plant, and equipment, net		1,053,132		493,053
Goodwill and intangible assets, net		3,309,177		860,645
Other assets		22,266		23,161
Total Assets	$	5,350,283	$	2,097,291
Liabilities and Equity
Current liabilities:
Accounts payable	$	116,336	$	99,340
Other current liabilities		243,634		183,991
Total Current Liabilities		359,970		283,331
Long-term debt		1,639,461		621,075
Other liabilities		361,029		119,239
Equity		2,989,823		1,073,646
Total Liabilities and Equity	$	5,350,283	$	2,097,291

STERIS plc

Segment Data

As a result of our recent combination with Synergy Health plc, which was completed on November 2, 2015, we have reassessed the organization of our business. Management will evaluate performance and allocate resources based on a segment operating income measure defined below. We have concluded that we operate and report in four reportable business segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. Corporate and other, which is presented separately, contains the Defense and Industrial business unit plus costs that are associated with being a publicly traded company and certain other corporate costs.

Financial information for each of our segments is presented in the following table. The accounting policies for reportable segments are the same as those for the consolidated Company. Operating income (loss) for each segment is calculated as the segment’s gross profit less direct expenses and indirect cost allocations, which results in the full allocation of all distribution and research and development expenses, and the partial allocation of corporate costs. These allocations are based upon variables such as segment headcount and revenues. In addition, the Healthcare Products segment is responsible for the management of all but two manufacturing facilities and uses standard cost to sell products to the other segments. Corporate and other includes the gross profit and direct expenses of the Defense and Industrial business unit, as well as certain unallocated corporate costs related to being a publicly traded company and legacy pension and post-retirement benefits. Adjustments include acquisition related costs, amortization of acquired intangibles, restructuring costs and other charges that management believes may or may not recur with similar materiality or impact on operating income in future periods. Management believes that by excluding these items they gain better insight and greater transparency of the operating performance of the segments, thus aiding them in more meaningful financial trend analysis and operational decision making.

	Three Months Ended December 31,						Nine Months Ended December 31,
(In thousands)	2015			2014			2015			2014
	(Unaudited)			(Unaudited)			(Unaudited)			(Unaudited)
Segment Revenues:
Healthcare Products	$	317,060		$	287,515		$	872,028		$	823,957
Healthcare Specialty Services		128,326			65,682			264,974			183,219
Life Sciences		82,702			67,997			210,514			185,759
Applied Sterilization Technologies		90,225			50,960			199,753			154,003
Total Reportable Segments		618,313			472,154			1,547,269			1,346,938
Corporate and Other		375			1,090			1,218			1,678
Total Segment Revenues	$	618,688		$	473,244		$	1,548,487		$	1,348,616
Segment Operating Income:
Healthcare Products	$	52,141		$	42,720		$	120,674		$	109,766
Healthcare Specialty Services		7,389			5,195			17,620			11,074
Life Sciences		24,115			16,482			58,448			41,615
Applied Sterilization Technologies		26,766			14,006			60,802			44,792
Total Reportable Segments		110,411			78,403			257,544			207,247
Corporate and Other		(2,648	)		(1,406	)		(8,580	)		(5,310	)
Total Segment Operating Income	$	107,763		$	76,997		$	248,964		$	201,937
Less: Adjustments
Restructuring charges	$	(193	)	$	(1,076	)	$	(657	)	$	(427	)
Amortization of acquired intangible assets		15,494			5,845			28,194			22,563
Acquisition and integration related charges		41,726			10,860			77,254			17,556
Amortization of inventory and property “step up” to fair value		4,060			22			4,102			1,310
Loss (gain) on fair value adjustment of acquisition related contingent consideration		—			—			—			1,998
Settlement of pension obligation		(46	)		—			26,470			—
Total operating income	$	46,722		$	61,346		$	113,601		$	158,937

STERIS plc

Consolidated Condensed Statements of Cash Flows

(In thousands)

	Nine Months Ended December 31,
	2015			2014
	(Unaudited)			(Unaudited)
Operating Activities:
Net income	$	53,716		$	93,665
Pension settlement expense		26,470			—
Pension contributions		(4,641	)		—
Non-cash items		76,408			75,401
Changes in operating assets and liabilities		(47,334	)		(3,856	)
Net cash provided by operating activities		104,619			165,210
Investing Activities:
Purchases of property, plant, equipment, and intangibles, net		(82,117	)		(56,757	)
Proceeds from sale of property, plant, equipment and intangibles		400			812
Investments in businesses, net of cash acquired		(604,682	)		(182,692	)
Purchases of investments		—			(4,681	)
Net cash used in investing activities		(686,399	)		(243,318	)
Financing Activities:
Proceeds from issuance of long-term obligations		350,000			—
(Payments) proceeds under credit facilities, net		348,670			117,200
Deferred financing fees and debt issuance costs		(5,094	)		(7,347	)
Repurchases of shares		(14,069	)		(20,110	)
Cash dividends paid to shareholders		(43,728	)		(39,790	)
Stock option and other equity transactions, net		10,944			19,245
Proceeds from issuance of equity to minority interest shareholders		488			—
Excess tax benefit from share-based compensation		5,909			8,880
Net cash provided by financing activities		653,120			78,078
Effect of exchange rate changes on cash and cash equivalents		(7,669	)		(8,260	)
Increase (decrease) in cash and cash equivalents		63,671			(8,290	)
Cash and cash equivalents at beginning of period		167,689			152,802
Cash and cash equivalents at end of period	$	231,360		$	144,512

The following table presents a financial measure which is considered to be “non-GAAP financial measures” under Securities Exchange Commission rules. Free cash flow is defined by the Company as cash flows from operating activities less purchases of property, plant, equipment and intangibles, net (capital expenditures) plus proceeds from the sale of property, plant, equipment and intangibles. The Company uses free cash flow as a measure to gauge its ability to fund future principal debt repayments and growth outside of core operations, repurchase common shares, and pay cash dividends. STERIS’s calculation of free cash flow may vary from other companies.

	Nine Months Ended
	December 31,
	2015			2014
	(Unaudited)			(Unaudited)
Calculation of Free Cash Flow:
Cash flows from operating activities	$	104,619		$	165,210
Purchases of property, plant, equipment, and intangibles, net		(82,117	)		(56,757	)
Proceeds from the sale of property, plant, equipment, and intangibles		400			812
Free Cash Flow	$	22,902		$	109,265

	Twelve Months Ended March 31, 2016
	(Outlook)*
Calculation of free cash flow for outlook:
Cash flows from operating activities	$	235,000
Purchases of property, plant, equipment, and intangibles, net		(135,000	)
Free Cash Flow	$	100,000

* All amounts are estimates.

STERIS plc

Non-GAAP Financial Measures

(In thousands, except per share data)

Non-GAAP financial measures are presented with the intent of providing greater transparency to supplemental financial information used by management and the Board of Directors in their financial analysis and operational decision making. These amounts are disclosed so that the reader has the same financial data that management uses with the belief that it will assist investors and other readers in making comparisons to our historical operating results and analyzing the underlying performance of our operations for the periods presented.

We believe that the presentation of these non-GAAP financial measures, when considered along with our GAAP financial measures and the reconciliation to the corresponding GAAP financial measures, provide the reader with a more complete understanding of the factors and trends affecting our business than could be obtained absent this disclosure. It is important for the reader to note that the non-GAAP financial measure used may be calculated differently from, and therefore may not be comparable to, a similarly titled measure used by other companies.

	Three months ended December 31, (unaudited)
	Gross Profit				Income from Operations						Net income attributable to shareholders						Diluted EPS
	2015		2014		2015			2014			2015			2014			2015		2014
GAAP	$	238,181	$	197,156	$	46,722		$	61,346		$	20,045		$	38,124		$	0.26	$	0.63
Adjustments:
Amortization of inventory and property “step up” to fair value		3,631		—		4,060			22			3,155			18			0.04		—
Amortization and impairment of acquired intangible assets		—		—		15,494			5,845			10,937			3,634			0.14		0.06
Acquisition related transaction and integration costs		1,531		—		41,726			10,860			35,616			6,625			0.46		0.11
Settlement of pension obligation		—		—		(46	)		—			(28	)		—			—		—
Restructuring		1		33		(193	)		(1,076	)		(117	)		(656	)		—		(0.01	)
Make whole payments (interest expense)		—		—		—			—			6,591			—			0.08		—
Adjusted	$	243,344	$	197,189	$	107,763		$	76,997		$	76,199		$	47,745		$	0.98	$	0.79

	Nine months ended December 31, (unaudited)
	Gross Profit					Income from Operations						Net income attributable to shareholders						Diluted EPS
	2015		2014			2015			2014			2015			2014			2015			2014
GAAP	$	631,592	$	561,241		$	113,601		$	158,937		$	53,023		$	93,665		$	0.80		$	1.56
Adjustments:
Amortization of inventory and property “step up” to fair value		3,631		1,234			4,102			1,310			3,188			1,049			0.05			0.02
Amortization and impairment of purchased intangible assets		—		—			28,194			22,563			18,818			13,976			0.29			0.23
Acquisition related transaction and integration costs		1,531		—			77,254			17,556			66,016			10,709			0.99			0.18
Loss (gain) on fair value adjustment of acquisition related contingent consideration		—		—			—			1,998			—			1,219			—			0.02
Settlement of pension obligation		—		—			26,470			—			16,337			—			0.25			—
Restructuring		319		(417	)		(657	)		(427	)		(400	)		(260	)		(0.01	)		—
Make whole payments (interest expense)		—		—			—			—			6,591			—			0.10			—
Adjusted	$	637,073	$	562,058		$	248,964		$	201,937		$	163,573		$	120,358		$	2.47		$	2.01

FY 2016 Outlook

	Twelve months ended March 31, 2016
	(Outlook)*
Net Income per diluted share	$	1.71 - 1.78
Amortization of inventory and property “step up” to fair value		0.11
Amortization and impairment of purchased intangible assets		0.47
Acquisition related transaction and integration costs		0.88
Settlement of pension obligation		0.23
Restructuring		(0.01	)
Make whole payments (interest expense)		0.09
Adjusted net income per diluted share	$	3.48 -  $3.55

* All amounts are estimates.

STERIS plc

Unaudited Supplemental Financial Data

Third Quarter Fiscal 2016

As of December 31 , 2015

	FY 2016			FY 2015			FY 2016			FY 2015
Total Company Revenues	Q3			Q3			YTD			YTD
Capital Equipment	$	167,718		$	151,217		$	437,976		$	415,100
Consumables		137,438			116,068			373,632			339,470
Service		313,532			205,959			736,879			594,046
Total Recurring		450,970			322,027			1,110,511			933,516
Total Revenues	$	618,688		$	473,244		$	1,548,487		$	1,348,616
United Kingdom Revenues	$	51,468		$	13,421		$	73,382		$	38,225
United Kingdom Revenues as a % of Total		8	%		3	%		5	%		3	%
United States Revenues	$	438,250		$	367,059		$	1,193,940		$	1,049,892
United States Revenues as a % of Total		71	%		78	%		77	%		78	%
International Revenues	$	128,970		$	92,764		$	281,165		$	260,499
International Revenues as a % of Total		21	%		20	%		18	%		19	%
Segment Data	Q3			Q3			YTD			YTD
Healthcare Products
Revenues
Capital Equipment	$	140,107		$	125,611		$	374,029		$	353,432
Consumables		101,748			88,592			277,555			257,334
Service		75,205			73,312			220,444			213,191
Total Recurring		176,953			161,904			497,999			470,525
Total Healthcare Products Revenues	$	317,060		$	287,515		$	872,028		$	823,957
Segment Operating Income		52,141			42,720			120,674			109,766
Healthcare Specialty Services
Healthcare Services Revenues	$	128,326		$	65,682		$	264,974		$	183,219
Segment Operating Income		7,389			5,195			17,620			11,074
Life Sciences
Revenues
Capital Equipment	$	26,636		$	24,733		$	61,456		$	59,073
Consumables		32,720			22,611			85,807			67,185
Service		23,346			20,653			63,251			59,501
Total Recurring		56,066			43,264			149,058			126,686
Total Life Sciences Revenues	$	82,702		$	67,997		$	210,514		$	185,759
Segment Operating Income		24,115			16,482			58,448			41,615
Applied Sterilization Technologies
Service Revenues	$	90,225		$	50,960		$	199,753		$	154,003
Segment Operating Income	$	26,766		$	14,006		$	60,802		$	44,792
Corporate and Other
Revenues	$	375		$	1,090		$	1,218		$	1,678
Operating Income (Loss)		(2,648	)		(1,406	)		(8,580	)		(5,310	)
Other Data	Q3			Q3			YTD			YTD
Healthcare Products Backlog	$	144,644		$	137,806			n/a			n/a
Life Sciences Backlog		45,370			43,748			n/a			n/a
Total Backlog	$	190,014		$	181,554			n/a			n/a
Free Cash Flow	$	(16,680	)	$	40,088		$	22,902		$	109,265
Net Debt	$	1,408,101		$	466,168			n/a			n/a

This supplemental data is consistent with publicly disclosed information provided in quarterly conference calls, earnings releases and SEC filings, and is subject to all definitions, precautions and limitations contained in those disclosures. Please see the Company’s most recent 10-K for definitions (and reconciliation where appropriate) of adjusted measures, backlog, free cash flow and net debt.

The following table provides historical data for Synergy Health in categories consistent with the future reporting of Synergy within the STERIS plc group.

The fiscal year of Synergy Health was the nearest weekend to the end of March each year. Accordingly reported quarters do not align to calendar quarters.

The accounting periods have been changed to calendar periods subsequent to the acquisition in November 2015.

Synergy Health

Fiscal 2015 and First Half Fiscal 2016 Revenue Data

Unaudited, Amounts in £000
	Synergy Health Three Months Ended June 2014		Synergy Health Three Months Ended September 2014		Synergy Health Three Months Ended December 2014		Synergy Health Three Months Ended March 2015		Synergy Health Three Months Ended June 2015		Synergy Health Three Months Ended September 2015
Revenues by type:
Product	£	11,035	£	11,436	£	11,535	£	10,984	£	10,307	£	9,869
Service		84,529		90,510		94,079		94,719		93,873		92,240
Total	£	95,564	£	101,946	£	105,614	£	105,703	£	104,180	£	102,109
Revenues by segment:
Healthcare Products	£	7,945	£	8,455	£	8,697	£	8,314	£	7,744	£	7,395
Healthcare Specialty Services		54,909		59,170		61,749		62,090		61,126		59,290
Applied Sterilization Technologies		32,710		34,321		35,168		35,299		35,310		35,423
Total	£	95,564	£	101,946	£	105,614	£	105,703	£	104,180	£	102,109
Revenues by location:
United Kingdom	£	39,574	£	41,435	£	42,458	£	42,346	£	41,656	£	41,739
United States		16,937		20,359		22,292		23,028		24,116		22,601
Europe, Middle East & Africa (1)		34,715		35,385		35,825		35,206		33,220		32,517
Asia Pacific and Latin America		4,338		4,767		5,039		5,123		5,188		5,252
Total	£	95,564	£	101,946	£	105,614	£	105,703	£	104,180	£	102,109

(1) Excludes United Kingdom which is presented in separate line.